EICHORPublic-registry site landscape for NCT04959032, “Lumateperone for the Prevention of Relapse in Patients With Schizophrenia”, a Schizophrenia study sponsored by Intra-Cellular Therapies, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04959032 (registry record) |
| Study title | Lumateperone for the Prevention of Relapse in Patients With Schizophrenia |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia |
| Sponsor | Intra-Cellular Therapies, Inc. |
| Condition(s) | Schizophrenia |
| Phase | PHASE3 |
| Listed sites | 43 |
| Intervention(s) | Lumateperone 42 mg, Placebo |
| Site countries | United States, Bulgaria, Poland, Serbia |
Patient-friendly overview of this study: eichor.com/study/NCT04959032.
Eichor generates a preliminary site-risk snapshot for NCT04959032 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Schizophrenia trials
← Eichor home · All tracked trials · Schizophrenia studies · Weekly briefs
